200 related articles for article (PubMed ID: 32913893)
1. Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy.
Crean RM; MacLachlan BJ; Madura F; Whalley T; Rizkallah PJ; Holland CJ; McMurran C; Harper S; Godkin A; Sewell AK; Pudney CR; van der Kamp MW; Cole DK
Mol Ther Oncolytics; 2020 Sep; 18():443-456. PubMed ID: 32913893
[TBL] [Abstract][Full Text] [Related]
2. Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy.
Simister PC; Border EC; Vieira JF; Pumphrey NJ
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851311
[TBL] [Abstract][Full Text] [Related]
3. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
[TBL] [Abstract][Full Text] [Related]
4. Engineering soluble T-cell receptors for therapy.
Robinson RA; McMurran C; McCully ML; Cole DK
FEBS J; 2021 Nov; 288(21):6159-6173. PubMed ID: 33624424
[TBL] [Abstract][Full Text] [Related]
5. Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition.
Szeto C; Bloom JI; Sloane H; Lobos CA; Fodor J; Jayasinghe D; Chatzileontiadou DSM; Grant EJ; Buckle AM; Gras S
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992915
[TBL] [Abstract][Full Text] [Related]
6. T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4.
Coles CH; McMurran C; Lloyd A; Hock M; Hibbert L; Raman MCC; Hayes C; Lupardus P; Cole DK; Harper S
J Biol Chem; 2020 Aug; 295(33):11486-11494. PubMed ID: 32532817
[TBL] [Abstract][Full Text] [Related]
7. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.
Baumgaertner P; Schmidt J; Costa-Nunes CM; Bordry N; Guillaume P; Luescher I; Speiser DE; Rufer N; Hebeisen M
Front Immunol; 2022; 13():973986. PubMed ID: 36032094
[TBL] [Abstract][Full Text] [Related]
8. Conserved Vδ1 Binding Geometry in a Setting of Locus-Disparate pHLA Recognition by δ/αβ T Cell Receptors (TCRs): Insight into Recognition of HIV Peptides by TCRs.
Shi Y; Kawana-Tachikawa A; Gao F; Qi J; Liu C; Gao J; Cheng H; Ueno T; Iwamoto A; Gao GF
J Virol; 2017 Sep; 91(17):. PubMed ID: 28615212
[TBL] [Abstract][Full Text] [Related]
9. Highly divergent T-cell receptor binding modes underlie specific recognition of a bulged viral peptide bound to a human leukocyte antigen class I molecule.
Liu YC; Miles JJ; Neller MA; Gostick E; Price DA; Purcell AW; McCluskey J; Burrows SR; Rossjohn J; Gras S
J Biol Chem; 2013 May; 288(22):15442-54. PubMed ID: 23569211
[TBL] [Abstract][Full Text] [Related]
10. Structure-Based, Rational Design of T Cell Receptors.
Zoete V; Irving M; Ferber M; Cuendet MA; Michielin O
Front Immunol; 2013 Sep; 4():268. PubMed ID: 24062738
[TBL] [Abstract][Full Text] [Related]
11. Structure-guided stabilization of pathogen-derived peptide-HLA-E complexes using non-natural amino acids conserves native TCR recognition.
Barber C; De Souza VA; Paterson RL; Martin-Urdiroz M; Mulakkal NC; Srikannathasan V; Connolly M; Phillips G; Foong-Leong T; Pengelly R; Karuppiah V; Grant T; Dembek M; Verma A; Gibbs-Howe D; Blicher TH; Knox A; Robinson RA; Cole DK; Leonard S
Eur J Immunol; 2022 Apr; 52(4):618-632. PubMed ID: 35108401
[TBL] [Abstract][Full Text] [Related]
12. Increased Peptide Contacts Govern High Affinity Binding of a Modified TCR Whilst Maintaining a Native pMHC Docking Mode.
Cole DK; Sami M; Scott DR; Rizkallah PJ; Borbulevych OY; Todorov PT; Moysey RK; Jakobsen BK; Boulter JM; Baker BM; Yi Li
Front Immunol; 2013; 4():168. PubMed ID: 23805144
[TBL] [Abstract][Full Text] [Related]
13. Normalized Synergy Predicts That CD8 Co-Receptor Contribution to T Cell Receptor (TCR) and pMHC Binding Decreases As TCR Affinity Increases in Human Viral-Specific T Cells.
Williams CM; Schonnesen AA; Zhang SQ; Ma KY; He C; Yamamoto T; Eckhardt SG; Klebanoff CA; Jiang N
Front Immunol; 2017; 8():894. PubMed ID: 28804489
[TBL] [Abstract][Full Text] [Related]
14. Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens.
MacLachlan BJ; Greenshields-Watson A; Mason GH; Schauenburg AJ; Bianchi V; Rizkallah PJ; Sewell AK; Fuller A; Cole DK
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287509
[TBL] [Abstract][Full Text] [Related]
15. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
16. A structural-based machine learning method to classify binding affinities between TCR and peptide-MHC complexes.
Dhusia K; Su Z; Wu Y
Mol Immunol; 2021 Nov; 139():76-86. PubMed ID: 34455212
[TBL] [Abstract][Full Text] [Related]
17. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVβ20-1, altering pHLA recognition.
Watkins S; Pichler WJ
PLoS One; 2013; 8(10):e76211. PubMed ID: 24116097
[TBL] [Abstract][Full Text] [Related]
18. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
19. TCR mimic compounds for pHLA targeting with high potency modalities in oncology.
Gerber HP; Presta LG
Front Oncol; 2022; 12():1027548. PubMed ID: 36338746
[TBL] [Abstract][Full Text] [Related]
20. Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.
Kim GB; Fritsche J; Bunk S; Mahr A; Unverdorben F; Tosh K; Kong H; Maldini CR; Lau C; Srivatsa S; Jiang S; Glover J; Dopkin D; Zhang CX; Schuster H; Kowalewski DJ; Goldfinger V; Ott M; Fuhrmann D; Baues M; Boesmueller H; Schraeder C; Schimmack G; Song C; Hoffgaard F; Roemer M; Tsou CC; Hofmann M; Treiber T; Hutt M; Alten L; Jaworski M; Alpert A; Missel S; Reinhardt C; Singh H; Schoor O; Walter S; Wagner C; Maurer D; Weinschenk T; Riley JL
Sci Transl Med; 2022 Aug; 14(660):eabo6135. PubMed ID: 36044599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
